Avantor Inc. Executive VP Benoit Gourdier to Depart Oct 14, 2026
$AVTR · Avantor, Inc.Research Summary
AI-generated summary of this SEC filing
Avantor Inc. Executive VP Benoit Gourdier to Depart Oct 14, 2026
What Happened
Avantor, Inc. (AVTR) filed a Form 8-K/A on August 27, 2026 updating an earlier 8-K (filed April 23, 2026) to disclose the departure date of Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products. Under a Transition Agreement reached August 21, 2026 (through subsidiary VWR International, LLC), Mr. Gourdier will remain employed through October 14, 2026, after which his employment will end.
Key Details
- Transition Agreement dated August 21, 2026; 8-K/A filed August 27, 2026.
- Mr. Gourdier’s employment ends on October 14, 2026.
- If he remains employed and complies with the Transition Agreement through that date, he will be eligible for severance benefits materially consistent with Avantor’s Executive Severance and Change in Control Plan (details in the company’s proxy filed March 27, 2026).
- The disclosure amends the April 23, 2026 Form 8-K which had announced his transition but did not include a departure date.
Why It Matters
This clarifies leadership timing for Avantor’s Bioscience and Medtech Products segment, giving investors a clear date for management transition and potential related costs (severance governed by the company’s executive plan). The filing does not disclose monetary severance amounts or a successor; investors should watch for further announcements about leadership replacements or related strategic updates.